Cantor Fitzgerald Comments on Collegium Pharmaceutical Inc’s FY2018 Earnings (COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Analysts at Cantor Fitzgerald decreased their FY2018 earnings estimates for shares of Collegium Pharmaceutical in a report issued on Tuesday, January 8th. Cantor Fitzgerald analyst B. Folkes now expects that the specialty pharmaceutical company will earn ($1.87) per share for the year, down from their previous estimate of ($1.83). Cantor Fitzgerald currently has a “Buy” rating and a $35.00 target price on the stock.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The firm had revenue of $70.20 million during the quarter, compared to analysts’ expectations of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The business’s revenue for the quarter was up 485.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.45) earnings per share.

Several other equities research analysts also recently commented on COLL. BidaskClub upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday, November 27th. ValuEngine upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday, November 13th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Collegium Pharmaceutical has an average rating of “Buy” and an average target price of $30.43.

Collegium Pharmaceutical stock opened at $15.95 on Friday. The stock has a market capitalization of $505.69 million, a PE ratio of -6.46 and a beta of 0.52. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. Collegium Pharmaceutical has a 12 month low of $13.70 and a 12 month high of $29.90.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the sale, the director now directly owns 361,000 shares in the company, valued at approximately $5,967,330. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 75,000 shares of company stock worth $1,282,750. Company insiders own 13.87% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $213,000. Atria Investments LLC increased its holdings in Collegium Pharmaceutical by 81.3% during the 3rd quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock worth $226,000 after purchasing an additional 6,866 shares during the last quarter. Jefferies Group LLC purchased a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $271,000. Capital Fund Management S.A. purchased a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $286,000. Finally, Man Group plc purchased a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $287,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Read More: No Load Funds

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply